Iovance Biotherapeutics, Inc. Stock News

The FDA grants accelerated approval to Iovance's (IOVA) Amtagvi (lifileucel) for treating advanced melanoma after anti-PD-1 and targeted therapy. Stock rises.

Iovance Biotherapeutics (NASDAQ: IOVA) stock price has rebounded this year and is hovering at its highest point since October 2022. It has risen by over 120% as investors focus on the upcoming earning

Iovance Biotherapeutics said on Friday the U.S. health regulator had granted accelerated approval for its cell therapy for adult patients with advanced melanoma, the first such treatment to be approve

SAN CARLOS, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor inf

Iovance Biotherapeutics could commercialize its lead program soon. However, a regulatory inquiry regarding a different program is a major risk.

Iovance Biotherapeutics could commercialize its first drug soon. It has a number of similar opportunities lined up for the next two years.

Iovance expects a regulatory decision on its candidate for advanced melanoma later this month. An approval would be the first for the company's innovative technology -- harnessing the body's own cells

Iovance Biotherapeutics just reported a significant problem in a clinical trial. It could still get approval for more than one program, and soon.

Iovance's tumor infiltrating lymphocyte cell therapy candidate, lifileucel, has shown promising results in a study of melanoma patients, with a 31.4% overall response rate. Lifileucel uses a novel mec

Iovance Biotherapeutics is preparing for the extended FDA deadline to determine the approval of lifileucel for advanced melanoma treatment. The FDA has put a clinical hold on the company's Phase II st

Iovance's (IOVA) surges on the anticipated FDA approval for its lead pipeline drug as the first individualized, one-time cell therapy for certain patients with melanoma.

Universal Stainless & Alloy Products (USAP), Lakeland Industries (LAKE), NGL Energy Partners (NGL) and Iovance Biotherapeutics (IOVA) have been selected as the breakout stocks for today.

The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a

Iovance jumped as investors assessed the fallout of yesterday's clinical hold on its IOV-LUN-202 clinical trial following a patient's death. The company is pausing enrollment for new patients during t

Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.